Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Although previous population-based studies have shown worse clinical outcomes for minority patients with DLBCL compared with white patients, this study reported no differences in PFS and OS were seen between the 2 groups.
A putative mechanism of resistance to BCMA-directed CAR-T therapy involves BCMA antigen loss through cleavage of BCMA from the surface of myeloma cells.
Little is currently known about how molecular alterations interact in the oncogenesis of follicular lymphoma.
For patients with early unfavorable Hodgkin lymphoma, disease control was improved with a dose-intensified regimen, but no overall survival gain was seen.
Addressing increased adverse events could be unmet medical need for Medicare-aged patients.
Combining vemurafenib with obinutuzumab in patients with relapsed or refractory HCL resulted in a complete response rate of 100% in the frontline setting.
Although allogeneic HSCT is considered the treatment of choice for patients with relapsed B-ALL, a number of potential barriers to its implementation can exist.
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
The second-generation Bruton tyrosine kinase inhibitor tirabrutinib (ONO/GS-4059) showed promising efficacy in patients with treatment-naive (TN) or relapsed/refractory (RR) Waldenström macroglobulinemia (WM).
